Abstract
Nanohybrid liposomes coated with amphiphilic hyaluronic acid-ceramide (HACE) was fabricated for targeted delivery of anticancer drug and in vivo cancer imaging. Nanohybrid liposomes including doxorubicin (DOX) and Magnevist, a contrast agent for magnetic resonance (MR) imaging, with 120-130 nm mean diameter and a narrow size distribution were developed. DOX release from the developed formulation was improved at acidic pH (pH 5.5 and 6.8) versus physiological pH (pH 7.4). Cytotoxicity induced by the blank plain liposome was reduced by coating the outer surface of the nanohybrid liposome with HACE. Cellular uptake of DOX from the nanohybrid liposome was enhanced by HA and CD44 receptor interaction, versus the plain liposome. In vivo contrast-enhancing effects revealed that the nanohybrid liposome can be used as a tumor targeting MR imaging probe for cancer diagnosis. In a pharmacokinetic study in rats, in vivo clearance of DOX was decreased in the order DOX solution, plain liposome (F2), and nanohybrid liposome (F3), indicating prolonged circulation of the drug in the blood stream and improved therapeutic efficacy of the nanohybrid liposome (F3). Based on these findings, the nanohybrid liposomal system may be a useful candidate for real-time cancer diagnosis and therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 98-108 |
| Number of pages | 11 |
| Journal | Journal of Controlled Release |
| Volume | 174 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2014 Jan 28 |
| Externally published | Yes |
Fingerprint
Keywords
- Doxorubicin
- Hyaluronic acid-ceramide
- Hybrid nanostructure
- Lipid
- Magnetic resonance imaging
ASJC Scopus subject areas
- Pharmaceutical Science
Cite this
Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. / Park, Ju Hwan; Cho, Hyun Jong; Yoon, Hong Yeol; Yoon, In Soo; Ko, Seung Hak; Shim, Jae Seong; Cho, Jee Hyun; Park, Jae Hyung; Kim, Kwang Meyung; Kwon, Ick Chan; Kim, Dae Duk.
In: Journal of Controlled Release, Vol. 174, No. 1, 28.01.2014, p. 98-108.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery
AU - Park, Ju Hwan
AU - Cho, Hyun Jong
AU - Yoon, Hong Yeol
AU - Yoon, In Soo
AU - Ko, Seung Hak
AU - Shim, Jae Seong
AU - Cho, Jee Hyun
AU - Park, Jae Hyung
AU - Kim, Kwang Meyung
AU - Kwon, Ick Chan
AU - Kim, Dae Duk
PY - 2014/1/28
Y1 - 2014/1/28
N2 - Nanohybrid liposomes coated with amphiphilic hyaluronic acid-ceramide (HACE) was fabricated for targeted delivery of anticancer drug and in vivo cancer imaging. Nanohybrid liposomes including doxorubicin (DOX) and Magnevist, a contrast agent for magnetic resonance (MR) imaging, with 120-130 nm mean diameter and a narrow size distribution were developed. DOX release from the developed formulation was improved at acidic pH (pH 5.5 and 6.8) versus physiological pH (pH 7.4). Cytotoxicity induced by the blank plain liposome was reduced by coating the outer surface of the nanohybrid liposome with HACE. Cellular uptake of DOX from the nanohybrid liposome was enhanced by HA and CD44 receptor interaction, versus the plain liposome. In vivo contrast-enhancing effects revealed that the nanohybrid liposome can be used as a tumor targeting MR imaging probe for cancer diagnosis. In a pharmacokinetic study in rats, in vivo clearance of DOX was decreased in the order DOX solution, plain liposome (F2), and nanohybrid liposome (F3), indicating prolonged circulation of the drug in the blood stream and improved therapeutic efficacy of the nanohybrid liposome (F3). Based on these findings, the nanohybrid liposomal system may be a useful candidate for real-time cancer diagnosis and therapy.
AB - Nanohybrid liposomes coated with amphiphilic hyaluronic acid-ceramide (HACE) was fabricated for targeted delivery of anticancer drug and in vivo cancer imaging. Nanohybrid liposomes including doxorubicin (DOX) and Magnevist, a contrast agent for magnetic resonance (MR) imaging, with 120-130 nm mean diameter and a narrow size distribution were developed. DOX release from the developed formulation was improved at acidic pH (pH 5.5 and 6.8) versus physiological pH (pH 7.4). Cytotoxicity induced by the blank plain liposome was reduced by coating the outer surface of the nanohybrid liposome with HACE. Cellular uptake of DOX from the nanohybrid liposome was enhanced by HA and CD44 receptor interaction, versus the plain liposome. In vivo contrast-enhancing effects revealed that the nanohybrid liposome can be used as a tumor targeting MR imaging probe for cancer diagnosis. In a pharmacokinetic study in rats, in vivo clearance of DOX was decreased in the order DOX solution, plain liposome (F2), and nanohybrid liposome (F3), indicating prolonged circulation of the drug in the blood stream and improved therapeutic efficacy of the nanohybrid liposome (F3). Based on these findings, the nanohybrid liposomal system may be a useful candidate for real-time cancer diagnosis and therapy.
KW - Doxorubicin
KW - Hyaluronic acid-ceramide
KW - Hybrid nanostructure
KW - Lipid
KW - Magnetic resonance imaging
UR - http://www.scopus.com/inward/record.url?scp=84888996200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888996200&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2013.11.016
DO - 10.1016/j.jconrel.2013.11.016
M3 - Article
C2 - 24280260
AN - SCOPUS:84888996200
VL - 174
SP - 98
EP - 108
JO - Journal of Controlled Release
JF - Journal of Controlled Release
SN - 0168-3659
IS - 1
ER -